Page last updated: 2024-12-11
siphonaxanthin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
siphonaxanthin: keto-carotenoid from Microthamnion (algae, green); RN is from 9th CI; cpd not in Chemline 9/17/82; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 11204185 |
SCHEMBL ID | 544364 |
MeSH ID | M0044337 |
Synonyms (5)
Synonym |
---|
LMPR01070158 |
siphonaxanthin |
SCHEMBL544364 |
(3e,5e,7e,9e,11e,13e,15e,17e)-3-(hydroxymethyl)-18-[(1r,4r)-4-hydroxy-2,6,6-trimethylcyclohex-2-en-1-yl]-1-[(4r)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-7,12,16-trimethyloctadeca-3,5,7,9,11,13,15,17-octaen-2-one |
XS177355 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" In addition, further studies are needed to determine its bioavailability and metabolic fate." | ( Siphonaxanthin, a green algal carotenoid, as a novel functional compound. Ganesan, P; Hirata, T; Li, Z; Manabe, Y; Sugawara, T, 2014) | 0.4 |
" However, little information on its in vivo bioavailability and biotransformation is available." | ( Absorption and Tissue Distribution of Siphonaxanthin from Green Algae. Hirata, T; Li, Z; Luo, X; Manabe, Y; Sugawara, T; Zheng, J, 2020) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (13.64) | 29.6817 |
2010's | 11 (50.00) | 24.3611 |
2020's | 8 (36.36) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (8.70%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (91.30%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |